Dec. 12, 2024 — The American Registry of Radiologic Technologists (ARRT) applauds Senators John Boozman (R-AR) and Ben Ray Lujan (D-NM) for introducing the Medicare Access to Radiology Care Act of 2024 (MARCA).

Dec. 4, 2024 - EDAP TMS SA, a leader in robotic energy-based therapies, recently announced the publication of the full results from the HIFI study in the peer-reviewed journal, European Urology. The study evaluated HIFU versus radical prostatectomy (RP) as a first line treatment of localized prostate cancer. The paper, “Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized, HIFI Trial,” is authored by Dr. Guillaume Ploussard from Department of Urology, UROSUD, Clinique La Croix du Sud, France.

 Dec. 16, 2024 — FUJIFILM Healthcare Americas Corporation has announced that its ASPIRE Cristalle Acquisition Workflow System (AWS), the workstation that is used in conjunction with the company’s 3D mammography system, has been granted a Risk Management Framework (RMF) and Authority to Operate (ATO) on U.S. Department of Defense (DoD) networks. 

Dec. 11, 2024 – A recently released study has introduced a novel approach to enhance the treatment of large sacral chordomas using carbon ion therapy. The study focuses on optimizing dose-averaged linear energy transfer (LETd), a critical parameter in radiotherapy that directly influences treatment efficacy for challenging tumors. The findings, published in Medical Physics, could significantly impact clinical outcomes for patients with these aggressive and resistant cancers.

Dec. 2, 2024 — GE HealthCare has agreed to acquire full ownership of Nihon Medi-Physics Co., Ltd (NMP), by purchasing from Sumitomo Chemical the 50% stake it does not already own. As part of GE HealthCare, NMP can build on its expertise developing and manufacturing proprietary and in-licensed radiopharmaceuticals used in single photon emission computed tomography (SPECT) and positron emission tomography (PET) molecular imaging procedures to detect and diagnose disease. Sumitomo and GE HealthCare expect the agreement to close in early 2025, subject to regulatory approvals.